United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$266.05 USD
+4.96 (1.90%)
Updated May 9, 2024 04:00 PM ET
After-Market: $265.84 -0.21 (-0.08%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 1 - 20 ( 586 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4/FY23: Rounding Out the Year of Tyvaso DPI w/ Another Record Revenue Quarter
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Near-Term Growth With TETON Program Broadening Upside; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2024 Outlook on Covered Companies Takeaways from Annual SF Biotech Meetings
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Federal Circuit Affirms ''793 PTAB Decision; Tyvaso DPI''s Dominance to Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department